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SCIENTIFIC OPINION 
Scientific Opinion on the substantiation of a health claim related to 
high-fibre sourdough rye bread and reduction of post-prandial glycaemic 
responses pursuant to Article 13(5) of Regulation (EC) No 1924/2006
1
 
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)
2,3
 
European Food Safety Authority (EFSA), Parma, Italy 
ABSTRACT 
Following an application from Oy Karl Fazer AB, submitted for authorisation of a health claim pursuant to 
Article 13(5) of Regulation (EC) No 1924/2006 via the Competent Authority of Finland, the EFSA Panel on 
Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver an opinion on the scientific substantiation 
of a health claim related to high-fibre sourdough rye bread and a reduction of post-prandial glycaemic responses. 
The Panel considers that the food, high-fibre sourdough rye bread, and its “comparator”, glucose, are sufficiently 
characterised in relation to the claimed effect. A reduction of post-prandial glycaemic responses might be a 
beneficial physiological effect. The Panel notes that in the four human intervention studies submitted as pertinent 
to the health claim the consumption of high-fibre sourdough rye bread induced a significant reduction of post-
prandial blood glucose responses when compared with glucose. The Panel also notes that, when comparable 
amounts of available carbohydrates from different carbohydrate-containing foods are tested, almost any 
carbohydrate-containing food would induce a reduction of post-prandial blood glucose responses compared with 
glucose. In addition, foods containing low amounts of, or no available carbohydrates, will also induce lower post-
prandial blood glucose responses when compared with glucose. The Panel concludes that a cause and effect 
relationship has been established between the consumption of almost any food and a reduction of post-prandial 
blood glucose responses as compared with glucose. However, the Panel considers that solid foods, including 
high-fibre sourdough rye bread, are generally not considered as an alternative to glucose solutions. In this 
context, conditions of use cannot be established for this health claim. 
© European Food Safety Authority, 2014 
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SUMMARY 
Following an application from Oy Karl Fazer AB, submitted for authorisation of a health claim 
pursuant to Article 13(5) of Regulation (EC) No 1924/2006 via the Competent Authority of Finland, 
the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver an opinion 
on the scientific substantiation of a health claim related to high-fibre sourdough rye bread and a 
reduction of post-prandial glycaemic responses. 
The scope of the application was proposed to fall under a health claim based on newly developed 
scientific evidence. The application included a request for the protection of proprietary data. 
The food that is the subject of the health claim is high-fibre sourdough rye bread, which should be 
consumed instead of glucose in order to obtain the claimed effect (i.e. reduction of post-prandial 
glycaemic responses). The Panel considers that the food, high-fibre sourdough rye bread, and its 
“comparator”, glucose, are sufficiently characterised in relation to the claimed effect. The Panel notes 
that high-fibre sourdough rye bread and glucose are not generally considered as alternatives to be 
consumed on similar occasions and/or for the same purpose. 
The claimed effect proposed by the applicant is “a reduced glycaemic response accompanied by a 
decreased insulin response after a meal”. The target population proposed by the applicant is the 
healthy adult population, including people with impaired glucose tolerance without diabetes. The 
Panel considers that a reduction of post-prandial glycaemic responses (as long as post-prandial 
insulinaemic responses are not disproportionately increased) might be a beneficial physiological 
effect. 
The applicant submitted four human intervention studies as being pertinent to the health claim. 
The Panel notes that in the four studies the consumption of high-fibre sourdough rye bread induced a 
significant reduction of post-prandial blood glucose responses when compared with glucose. In 
addition, two studies showed a reduction of insulinaemic responses after consumption of high-fibre 
sourdough rye bread when compared with glucose. 
The Panel also notes that, when comparable amounts of available carbohydrates from different 
carbohydrate-containing foods are tested, almost any carbohydrate-containing food would induce a 
reduction of post-prandial blood glucose responses compared with the blood glucose responses 
elicited by the consumption of glucose. In addition, the Panel notes that foods containing low amounts 
of, or no available carbohydrates, will also induce lower post-prandial blood glucose responses when 
compared with glucose.  
The Panel concludes that a cause and effect relationship has been established between the 
consumption of almost any food and a reduction of post-prandial blood glucose responses as 
compared with glucose. 
However, the Panel considers that solid foods, including high-fibre sourdough rye bread, are generally 
not considered as an alternative (i.e. to be consumed on similar occasions and/or for the same 
purpose) to glucose solutions. In this context, conditions of use cannot be established for this health 
claim. 
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BACKGROUND 
Regulation (EC) No 1924/2006
4
 harmonises the provisions that relate to nutrition and health claims, 
and establishes rules governing the Community authorisation of health claims made on foods. As a 
rule, health claims are prohibited unless they comply with the general and specific requirements of 
this Regulation, are authorised in accordance with this Regulation, and are included in the lists of 
authorised claims provided for in Articles 13 and 14 thereof. In particular, Article 13(5) of this 
Regulation lays down provisions for the addition of claims (other than those referring to the reduction 
of disease risk and to children’s development and health) which are based on newly developed 
scientific evidence, or which include a request for the protection of proprietary data, to the 
Community list of permitted claims referred to in Article 13(3). 
According to Article 18 of this Regulation, an application for inclusion in the Community list of 
permitted claims referred to in Article 13(3) shall be submitted by the applicant to the national 
competent authority of a Member State, which will make the application and any supplementary 
information supplied by the applicant available to the European Food Safety Authority (EFSA). 
STEPS TAKEN BY EFSA 
 The application was received on 09/01/2014. 
 The scope of the application was proposed to fall under a health claim based on newly 
developed scientific evidence. The application included a request for the protection of 
proprietary data. 
 On 14/03/2014, during the validation process of the application, EFSA sent a request to the 
applicant to provide missing information. 
 On 19/03/2014, EFSA received the missing information as submitted by the applicant. 
 The scientific evaluation procedure started on 21/03/2014. 
 On 07/05/2014, the Working Group on Claims of the NDA Panel agreed on a list of questions 
for the applicant to provide additional information to accompany the application. The clock 
was stopped on 19/05/2014 and was restarted on 03/06/2014, in compliance with 
Article 18(3) of Regulation (EC) No 1924/2006. 
 On 10/06/2014, EFSA received the requested information (which was made available to 
EFSA in electronic format on 30/05/2014). 
 During its meeting on 19/09/2014, the NDA Panel, having evaluated the data submitted, 
adopted an opinion on the scientific substantiation of a health claim related to sourdough rye 
bread and a reduction of post-prandial glycaemic responses. 
TERMS OF REFERENCE 
EFSA is requested to evaluate the scientific data submitted by the applicant in accordance with 
Article 16(3) of Regulation (EC) No 1924/2006. On the basis of that evaluation, EFSA will issue an 
opinion on the scientific substantiation of a health claim related to: high-fibre sourdough rye bread 
and a reduction of post-prandial glycaemic responses. 
                                                     
4 Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and 
health claims made on foods. OJ L 404, 30.12.2006, p. 9–25. 
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EFSA DISCLAIMER 
The present opinion does not constitute, and cannot be construed as, an authorisation for the 
marketing of high-fibre sourdough rye bread, a positive assessment of its safety, nor a decision on 
whether high-fibre sourdough rye bread is, or is not, classified as a foodstuff. It should be noted that 
such an assessment is not foreseen in the framework of Regulation (EC) No 1924/2006. 
It should also be highlighted that the scope, the proposed wording of the claim, and the conditions of 
use as proposed by the applicant may be subject to changes, pending the outcome of the authorisation 
procedure foreseen in Article 18(4) of Regulation (EC) No 1924/2006. 
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INFORMATION PROVIDED BY THE APPLICANT 
Applicant’s name and address: Oy Karl Fazer AB, PL 4, FI-00941 Helsinki, Finland. 
The application includes a request for the protection of proprietary data for six unpublished studies 
(Blanco and Granfeldt, 2006; Henry and Lightowler, 2006, 2007a, b; Suutari et al., 2012; Niskanen et 
al., 2013), in accordance with Article 21 of Regulation (EC) No 1924/2006. 
Food/constituent as stated by the applicant 
According to the applicant, the food that is the subject of the health claim is high-fibre sourdough rye 
bread with a minimum content of 70 % rye (whole-grain) and a maximum content of 30 % wheat, oat 
or barley of the total cereal content. The bread is manufactured by natural sourdough fermentation 
and contains at least 10 g fibre per 100 g (10-16 g/100 g). The typical acidity values of the bread are 
pH ≤ 4.7 and total titratable acidity (TTA) of ≥ 8.5 mL (0.1 M NaOH/10 g bread). 
Health relationship as claimed by the applicant 
According to the applicant, the consumption of high-fibre sourdough rye bread contributes to a 
reduced glycaemic response accompanied by a decreased insulin response after a meal. 
The applicant claims that the main mechanism by which the food exerts the claimed effect is a 
hindrance of carbohydrate digestion and absorption in the small intestine, which leads to a lower and 
delayed rise of post-prandial blood glucose levels, and decreased insulin levels. The applicant also 
claims delayed gastric emptying owing to the presence of intact/dense structures not accessible to 
human amylases, a high fibre content and a high amount of organic acids (low pH) in the bread; and 
inhibition of digestive enzymes because of low pH and soluble fibre content. Furthermore, the 
applicant hypothesised that the high polyphenol content, in addition to zinc, in rye bread may 
contribute to the effect by inhibiting carbohydrate-metabolising enzymes or glucose transport. 
Wording of the health claim as proposed by the applicant 
The applicant has proposed the following wording for the health claim: “Consumption of high-fibre 
sourdough rye bread contributes to a reduction of glycaemic response accompanied with a decreased 
insulin response after a meal”. 
Specific conditions of use as proposed by the applicant 
The applicant proposed a daily intake of 100 g high-fibre sourdough rye bread. The proposed target 
population is the healthy adult population, including also people with impaired glucose tolerance 
without diabetes. 
ASSESSMENT 
1. Characterisation of the food/constituent 
The food that is the subject of the health claim is high-fibre sourdough rye bread, which should be 
consumed instead of glucose in order to obtain the claimed effect (i.e. reduction of post-prandial 
glycaemic responses). 
The content of rye (Secale cereale) ingredients (flour, flake, cut and crushed grain, whole kernels 
and/or rye bran) in the bread amounts to at least 70 % of all the cereals used, with the remaining 30 % 
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being wheat, oat or barley (flour or grain). Part of the rye is included in the sourdough and, thus, is 
fermented during the incubation process. Other ingredients are water, yeast and salt. Furthermore, 
small amounts of spices, malt extract or syrup may be added. No butter, oil or extra acids are added. 
The bread is manufactured in a one-stage sourdough process with at least eight hours of fermentation, 
which leads to the dense structure and acidity of the bread. The typical acidity values of the bread are 
pH ≤ 4.7 and total titratable acidity (TTA) of ≥ 8.5 mL (0.1 M NaOH/10 g bread). The fibre content 
in the bread varies from 10-16 g/100 g and comprises 4-9 g/100 g soluble fibre and 8-11 g/100 g 
insoluble fibre. The typical nutrient composition of high-fibre sourdough rye bread was provided. 
An overview of the manufacturing process, stability data and batch-to-batch variability were provided. 
The applicant claimed that consumption of high-fibre sourdough rye bread would reduce post-
prandial blood glucose and insulinaemic responses and presented four human intervention studies as 
being pertinent to the claim. In all four studies (Blanco and Granfeldt, 2006; Henry and Lightowler, 
2006; Suutari et al., 2012; Niskanen et al., 2013; all four unpublished and claimed as proprietary by 
the applicant), various types of high-fibre sourdough rye bread were tested for their ability to reduce 
post-prandial blood glucose responses in comparison with a glucose reference drink. 
EFSA informed the applicant that claims on the reduction of post-prandial blood glucose responses 
refer to the ability of a food/constituent to reduce the blood glucose rise after consumption of a food 
or meal rich in available carbohydrates in comparison with a reference food or meal, and that, 
therefore, such claims are considered comparative claims (EFSA NDA Panel, 2011). The applicant 
was also informed that, in presenting such claims, applicants should take into account the Guidance 
on the implementation of Regulation (EC) No 1924/2006 of the Standing Committee on the Food 
Chain and Animal Health for the use of comparative claims
5
, which specifies that a comparison may 
only be made between foods of the same category, that the notion of food category should also take 
account of the occasion of consumption and/or the purpose of the consumption, and that the reference 
product should be explicitly mentioned. 
 
In this context, the applicant was requested to specify and characterise the food/constituent that is the 
subject of the health claim and the food/constituent that is being used as the comparator (reference). 
In reply, the applicant indicated that glucose was the reference food with which the high-fibre 
sourdough rye bread should be compared in relation to the claimed effect. 
EFSA issued positive opinions in relation to the proposed claimed effect (i.e. reduction of post-
prandial blood glucose responses) in the following cases: 
 sugars (e.g. fructose) were intended to replace other sugars (e.g. glucose, sucrose) within the 
same food/beverage (EFSA NDA Panel, 2011b); 
 food/constituents with no effect or a reduced effect on post-prandial blood glucose responses 
(e.g. non/low-digestible carbohydrates, intense sweeteners and sugar alcohols) were intended 
to replace food/constituents (e.g. sugars, other digestible carbohydrates) with an independent 
role in increasing post-prandial glycaemic responses within the same food/beverage (EFSA 
NDA Panel, 2011c, d, g, h, 2014); 
 food/constituents (e.g. different types of dietary fibre) which, when present in carbohydrate-
containing foods, could reduce post-prandial blood glucose responses to such foods by, for 
example, decreasing the rate of absorption of available carbohydrates. In these cases, the 
reference food/beverage was the test food/beverage without the food/constituent for which the 
claim was made (EFSA NDA Panel, 2010a, b, 2011e, f, 2012). 
                                                     
5  Guidance on the implementation of Regulation (EC) No 1924/2006 on nutrition and health claims made on foods – 
Conclusions of the Standing Committee on the Food Chain and Animal Health, 14 December 2007.  
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In all these aforementioned cases, the test food/beverage and the reference food/beverage were 
considered as alternative products to be consumed on similar occasions and/or for the same purpose. 
The Panel notes that high-fibre sourdough rye bread and glucose are not generally considered as 
alternatives to be consumed on similar occasions and/or for the same purpose. 
The Panel considers that the food, high-fibre sourdough rye bread, which is the subject of the health 
claim, and its “comparator”, glucose, are sufficiently characterised in relation to the claimed effect. 
2. Relevance of the claimed effect to human health 
The claimed effect proposed by the applicant is “a reduced glycaemic response accompanied by a 
decreased insulin response after a meal”. The target population proposed by the applicant is the 
healthy adult population, including people with impaired glucose tolerance without diabetes. 
The elevation of blood glucose concentrations after consumption of a food and/or meal, i.e. post-
prandial glycaemia, is a normal physiological response which varies in magnitude and duration, and 
which may be influenced by the chemical and physical nature of the food or meal consumed, as well 
as by individual factors (Venn and Green, 2007). Decreasing post-prandial glycaemic responses may, 
for example, be beneficial to individuals with impaired glucose tolerance, as long as post-prandial 
insulinaemic responses are not disproportionately increased. Impaired glucose tolerance is common in 
the general population of adults. 
The Panel considers that a reduction of post-prandial glycaemic responses (as long as post-prandial 
insulinaemic responses are not disproportionately increased) might be a beneficial physiological 
effect. 
3. Scientific substantiation of the claimed effect 
The applicant performed a literature search in PubMed and the Cochrane Database of systematic 
reviews using the search terms “rye”, “bread”, “glucose”, “insulin”, “postprandial”, “glycemic”, 
“glycaemic” and “response” in various combinations. In addition to this search, the reference lists of 
articles were screened manually. Studies were included if they were intervention or observational 
trials, used rye bread (containing more than 50 % rye of all cereal ingredients) as a study product, 
assessed post-prandial effects on glucose and, if possible, insulin response, used glucose as a 
reference product and were carried out in study subjects with normal or impaired glucose metabolism. 
Studies performed in subjects with non-insulin-dependent or insulin-dependent diabetes mellitus were 
excluded. 
The applicant submitted four human intervention studies as being pertinent to the health claim 
(Blanco and Granfeldt, 2006; Henry and Lightowler, 2006; Suutari et al., 2012; Niskanen et al., 2013; 
all four unpublished and claimed as proprietary by the applicant). 
In these four cross-over studies, various high-fibre sourdough rye breads were tested for their ability 
to reduce post-prandial blood glucose responses in comparison with a glucose reference drink. 
Standard methodology (Wolever et al., 2003; Wolever, 2004; Brouns et al., 2005) was used to 
determine the blood glucose incremental areas under the curve (iAUC) of the breads. The sourdough 
rye breads used in the four studies complied with the specifications indicated in section 1. The Panel 
notes that in the four studies (Blanco and Granfeldt, 2006; Henry and Lightowler, 2006; Suutari et al., 
2012; Niskanen et al., 2013), submitted as pertinent for the scientific substantiation of the claim, the 
consumption of high-fibre sourdough rye bread induced a significant reduction of post-prandial blood 
glucose responses when compared with glucose. In addition, two studies (Suutari et al., 2012; 
Niskanen et al., 2013) showed a reduction of insulinaemic responses after consumption of high-fibre 
sourdough rye bread when compared with glucose. 
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The Panel also notes that, when comparable amounts of available carbohydrates from different 
carbohydrate-containing foods are tested, almost any carbohydrate-containing food would induce a 
reduction of post-prandial blood glucose responses compared with the blood glucose responses 
elicited by the consumption of glucose (Foster-Powell et al., 2002; Atkinson et al., 2008). In addition, 
the Panel notes that foods containing low amounts of carbohydrates or no available carbohydrates will 
also induce lower post-prandial blood glucose responses when compared with glucose. 
The Panel concludes that a cause and effect relationship has been established between the 
consumption of almost any food and a reduction of post-prandial blood glucose responses as 
compared with glucose.  
The Panel could have reached this conclusion without the human studies (Blanco and Granfeldt, 
2006; Henry and Lightowler, 2006; Suutari et al., 2012; Niskanen et al., 2013) claimed as proprietary 
by the applicant. 
However, the Panel considers that solid foods, including high-fibre sourdough rye bread, are generally 
not considered as an alternative (i.e. to be consumed on similar occasions and/or for the same 
purpose) to glucose solutions. In this context, the Panel cannot establish conditions of use for this 
claim.  
4. Wording 
The Panel considers that the following wording reflects the scientific evidence: “Consumption of 
almost any food instead of glucose induces a lower blood glucose rise”. 
5. Conditions of use 
The Panel considers that solid foods, including high-fibre sourdough rye bread, are generally not 
considered as an alternative (i.e. to be consumed on similar occasions and/or for the same purpose) to 
glucose solutions. In this context, conditions of use cannot be established for this claim. 
CONCLUSIONS 
On the basis of the data presented, the Panel concludes that: 
 The food, high-fibre sourdough rye bread, which is the subject of the health claim, and its 
“comparator”, glucose, are sufficiently characterised in relation to the claimed effect. 
 The claimed effect is “a reduced glycaemic response accompanied by a decreased insulin 
response after a meal”. The target population proposed by the applicant is the healthy adult 
population, including people with impaired glucose tolerance without diabetes. A reduction of 
post-prandial glycaemic responses might be a beneficial physiological effect. 
 A cause and effect relationship has been established between the consumption of almost any 
food and a reduction of post-prandial blood glucose responses as compared with glucose. 
 The following wording reflects the scientific evidence: “Consumption of almost any food 
instead of glucose induces a lower blood glucose rise”. 
 Solid foods, including high-fibre sourdough rye bread, are generally not considered as an 
alternative to glucose solutions. In this context, conditions of use cannot be established for 
this claim. 
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DOCUMENTATION PROVIDED TO EFSA 
Health claim application on high-fibre sourdough rye bread and a reduction of post-prandial 
glycaemic responses pursuant to Article 13(5) of Regulation (EC) No 1924/2006 (Claim serial No: 
0405_FI). January 2014. Submitted by Oy Karl Fazer AB. 
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